期刊文献+

ⅠA期乳腺癌临床病理特征及预后相关因素分析 被引量:3

Clinicopathologic characteristics and prognostic factors of stage Ⅰ_A breast cancer
原文传递
导出
摘要 目的:探讨Ⅰ_A期乳腺癌患者的临床病理特征与预后因素。方法:回顾性分析2004年1月—2009年12月天津医科大学肿瘤医院收治的156例IA期(T1N0M0,)乳腺癌患者的临床病理资料。结果:156例患者均为女性;病理类型以浸润性导管癌为主(115例,73.7%);原发肿瘤大小以T1c居多(77例,49.4%);组织学分级以II级(79例,50.6%)及III级(58例,37.2%)为主。5年无进展生存(PFS)为93.3%,5年总生存(OS)为99.1%。单因素分析结果显示,组织学分级、Ki-67表达及淋巴脉管侵犯与患者的PFS有关(均P<0.05);多因素分析显示,组织学分级及Ki-67表达情况是影响患者PFS的独立预后因素(均P<0.05)。结论:IA期乳腺癌患者虽然总体预后较好,但对于某些亚组患者而言,预后较差,该类患者的复发转移风险较大。 Objective: To investigate the clinicopathologic characteristics and prognostic factors of patients with stage IA breast cancer. Methods: The clinicopathologic data of 156 patients with IA stage (T1N0M0) breast cancer treated in Cancer Hospital of Tianjin Medical University from January 2004 to December 2009were retrospectively analyzed. Results: Of the 156 patients, all cases were female; inifltrate ductal carcinoma accounted for the majority of the pathological types (115 cases, 73.7%), the primary tumor sizes were mostly classiifed as T1c (77 cases, 49.4%)and histological grades were mainly grade II (79 cases, 50.6%) and III (58 cases, 37.2%). hTe 5-year progress-free survival (PFS) was 93.3% and overall survival (OS) was 99.1%, respectively. Univariate analysis showed that histological grade, Ki-67 expression and lymphvascular invasion were significantly related to the PFS of the patients (allP〈0.05). Multivariate analysis identified that histological grade and Ki-67 expression were independent prognostic factors for PFS of the patients (bothP〈0.05). Conclusion: Although the overall prognosis of stage IA breast cancer patients is favorable, patients in some subgroups still have great risk of recurrence and metastases, and they have a poor prognosis.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2016年第8期1193-1197,共5页 China Journal of General Surgery
基金 国家科技支撑计划资助项目(2005BAI12B15)
关键词 乳腺肿瘤 无病生存 危险因素 Breast Neoplasms Disease-Free Survival Risk Factors
  • 相关文献

参考文献22

  • 1Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]_ CA Cancer JClin, 2014, 64(1):9-29. 被引量:1
  • 2Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High riskof recurrence for patients with breast cancer who have humanepidermal growth factor receptor 2-positive, node-negative tumors1 cm or smaller[J], J Clin Oncol, 2009, 27(34):5700-5706. 被引量:1
  • 3Le Du F, Eckhardt BL, Lim B, et al. Is the future of personalizedtherapy in triple-negative breast cancer based on molecularsubtype? [J] .Oncotarget, 2015,6(15):12890-12908. 被引量:1
  • 4Parinyanitikul N, Lei X, Chavez-MacGregor M, et al. Receptorstatus change from primary to residual breast cancer afterneoadjuvant chemotherapy and analysis of survival outcomes[J].Clin Breast Cancer, 2015,15(2):153-160. 被引量:1
  • 5Gamucci T, Vaccaro A, Ciancola F, et al. Recurrence risk in small,node-negative, early breast cancer: a multicenter retrospectiveanalysis[J]. J Cancer Res Clin Oncol, 2013, 139(5):853-860. 被引量:1
  • 6Gonzalez-Angulo AM, Akcakanat A, Liu S, et al. Open-labelrandomized clinical trial of standard neoadjuvant chemotherapywith paclitaxel followed by FEC versus the combination ofpaclitaxel and everolimus followed by FEC in women with triplereceptor-negative breast cancer[J]. Ann Oncol, 2014, 25(6):1122-1127. 被引量:1
  • 7Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumorsubtype and treatment pattern in women with small, node-negativebreast cancer: a multi-institutional study[J]. J Clin Oncol, 2014,32(20):2142-2150. 被引量:1
  • 8Vaz-Luis I,Ottesen RA, Hughes ME, et al. Impact of hormonereceptor status on patterns of recurrence and clinical outcomesamong patients with human epidermal growth factor-2-positivebreast cancer in the National Comprehensive Cancer Network: aprospective cohort study[J]. Breast Cancer Res, 2012, 14(5):R129.doi: 10.1186/bcr3324. 被引量:1
  • 9Colleoni M, Cole BF, Viale G, et al. Classical cyclophosphamide,methotrexate, and fluorouracil chemotherapy is more effectivein triple-negative, node-negative breast cancer: results from tworandomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer[J]. J Clin Oncol, 2010, 28(18):2966-2973. 被引量:1
  • 10Galimberti V,Cole BF, Zurrida S, et al. Axillary dissection versusno axillary dissection in patients with sentinel-node micrometastases(IBCSG 23-01): a phase 3 randomised controlled trial[J]. LancetOncol, 2013, 14(4):297-305. 被引量:1

二级参考文献31

  • 1Nadkarni MS, Rangole AK, Sharma RK, et al. Influence of surgical technique on axi|lary seroma formation: a randomized study[J]. ANZ J Surg, 2007, 77(5):385-389. 被引量:1
  • 2Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer[J]. Adv Exp Med Biol, 2007, 605:1-22. 被引量:1
  • 3周华宁,卢冰,栗惠芹.乳腺癌术后大分割短疗程放疗的远期结果分析[J].中华放射肿瘤学杂志,2007,16(6):435-438. 被引量:7
  • 4Clarke M, Collins R, Darhy S, et al. Effects of radiotherapy and of differences in the exlent of surgery for early breast cancer on local reeurrence and 15-year survival: an overview of the randomized trial[J]. Lancet, 2005, 366(9503):2087-2106. 被引量:1
  • 5Reintgen C, Reintgen D, Solin LJ. Advances in local-regional treatment for patients with early-stage breast cancer: a review of the field[J]. Clin Breast Cancer, 2010, 10(3):180-187. 被引量:1
  • 6Vaidya JS, Tobias JS, Baum M, et at. Intraoperative radiotherapy for breast cancer[J]. Lancet Oncol, 2004, 5(3): 165-173. 被引量:1
  • 7Vaidya JS, Joseph DJ, Tobias JS, el al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non- inferiority phase 3 trial[J]. Lancet, 2010, 376(9735):91-102. 被引量:1
  • 8Osti MF, Carnevale A, Bracci S, et al. Exclusive electron intraoperative radiotherapy in early-stage breast cancer: a monoinstitulional experience[J]. Anticancer Res, 2013, 33(3):1229- 1235. 被引量:1
  • 9Stmad V, Hildebrandt G, Petter R, et al. Accelerated partial breast irradiation: 5-year results of the German-Austrian multieenter phase II trial using interstitial multieatheter braehytherapy alone after breast-conserving surgery[J].lnt J Radiat Oncol Biol Phys, 2011, 80(1):17-24. 被引量:1
  • 10Belkacdmi Y, Chauvet MP, Giard S, et al. Partial breast irradiation as sole therapy for low risk breast carcinoma: early toxicity, cosmesis and quality of life results of a MammoSite brachytherapy phase 11 study[J]. Radiother Oneol, 2009, 90(1):23-29. 被引量:1

共引文献39

同被引文献38

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部